Optinose Expects XHANCE Net Revenues For FY24 To Be Between $85M-$95M; Sees Average XHANCE Net Revenue Per Prescription To Exceed $230 (Prior View: $220)
Optinose Expects XHANCE Net Revenues For FY24 To Be Between $85M-$95M; Sees Average XHANCE Net Revenue Per Prescription To Exceed $230 (Prior View: $220)
Optinose預計，XHANCE24財年的淨收入將在8500萬至9500萬美元之間；預計每張處方的平均XHANCE淨收入將超過230美元（先前觀點：220美元）
Operating Expenses
The Company expects total GAAP operating expenses (selling, general & administrative expenses and research & development expenses) for 2024 to be between $95.0 to $101.0 million, of which the Company expects stock-based compensation to be approximately $6.0 million.
運營費用
該公司預計，2024年的GAAP總運營支出（銷售、一般和管理費用以及研發費用）將在9,500萬美元至1.01億美元之間，公司預計其中股票薪酬約爲600萬美元。
Net Income from Operations
The Company expects to product positive income from operations (GAAP) for full year 2025.
運營淨收入
該公司預計2025年全年將產生正運營收入（GAAP）。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。